Biology Reference
In-Depth Information
American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll
Cardiol 53:1573-1619
Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S (2002) Oral sildenafil is an
effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension:
comparison with inhaled nitric oxide. Circulation 105:2398-2403
Millen J, MacLean MR, Houslay MD (2006) Hypoxia-induced remodelling of PDE4 isoform
expression and cAMP handling in human pulmonary artery smooth muscle cells. Eur J Cell
Biol 85:679-691
Miller CL, Oikawa M, Cai Y, Wojtovich AP, Nagel DJ, Xu X, Xu H, Florio V, Rybalkin SD,
Beavo JA, Chen YF, Li JD, Blaxall BC, Abe J, Yan C (2009) Role of Ca2+/calmodulin-
stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy.
Circ Res 105:956-964
Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR,
Thistlethwaite PA, Weissmann N, Yuan JX, Weir EK (2009) Cellular and molecular basis of
pulmonary arterial hypertension. J Am Coll Cardiol 54:S20-S31
Mouchaers KT, Schalij I, Versteilen AM, Hadi AM, van Nieuw Amerongen GP, van Hinsbergh VW,
Postmus PE, van der Laarse WJ, Vonk-Noordegraaf A (2009) Endothelin receptor blockade
combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity
in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 297:H200-H207
Mullershausen F, Friebe A, Feil R, ThompsonWJ, Hofmann F, Koesling D (2003) Direct activation
of PDE5 by cGMP: long-term effects within NO/cGMP signaling. J Cell Biol 160:719-727
Murray F, MacLean MR, Pyne NJ (2002) Increased expression of the cGMP-inhibited cAMP-
specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of
pulmonary hypertension. Br J Pharmacol 137:1187-1194
Murray F, MacLean MR, Pyne NJ (2003) An assessment of the role of the inhibitory gamma
subunit of the retinal cyclic GMP phosphodiesterase and its effect on the p42/p44 mitogen-
activated protein kinase pathway in animal and cellular models of pulmonary hypertension. Br
J Pharmacol 138:1313-1319
Murray F, Patel HH, Suda RY, Zhang S, Thistlethwaite PA, Yuan JX, Insel PA (2007) Expression
and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells
from patients with pulmonary hypertension: role for PDE1. Am J Physiol Lung Cell Mol
Physiol 292:L294-L303
Muzaffar S, Shukla N, Bond M, Sala-Newby GB, Newby AC, Angelini GD, Jeremy JY (2008)
Superoxide from NADPH oxidase upregulates type 5 phosphodiesterase in human vascular
smooth muscle cells: inhibition with iloprost and NONOate. Br J Pharmacol 155:847-856
Nagel DJ, Aizawa T, Jeon KI, Liu W, Mohan A, Wei H, Miano JM, Florio VA, Gao P, Korshunov
VA, Berk BC, Yan C (2006) Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase
1A in vascular smooth muscle cell growth and survival. Circ Res 98:777-784
Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L,
Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED (2007) Phosphodiesterase type 5 is
highly expressed in the hypertrophied human right ventricle, and acute inhibition of phospho-
diesterase type 5 improves contractility. Circulation 116:238-248
Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R,
Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG,
Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W (2002)
Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322-329
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH,
Bommer WJ, Elkayam U, Kukin ML et al (1991) Effect of oral milrinone on mortality in
severe chronic heart
failure. The PROMISE Study Research Group. N Engl J Med
325:1468-1475
Palmer D, Maurice DH (2000) Dual expression and differential regulation of phosphodiesterase
3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodi-
esterase 3 inhibition in human cardiovascular tissues. Mol Pharmacol 58:247-252
